Antibody-drug conjugates for cancer therapy: Chemistry to clinical implications

Pharmaceuticals

Volumn 11, Issue 2, 2018, Pages

  Dan, Nirnoy ^a   Setua, Saini ^a   Kashyap, Vivek K ^a   Khan, Sheema ^a   Jaggi, Meena ^a   Yallapu, Murali M ^a   Chauhan, Subhash C ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antibody; Cancer therapy; Chemical linker; Drug conjugation; Drug delivery

Indexed keywords

AMINO ACID DERIVATIVE; ANTIBODY; ANTINEOPLASTIC AGENT; CHEMICAL COMPOUND; CLEAVABLE LINKER; CYSTEINE; LYSINE; NON CLEAVABLE LINKER; UNCLASSIFIED DRUG; UNNATURAL AMINO ACID;

ANTIBODY DRUG CONJUGATION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMICAL ENGINEERING; CHEMISTRY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DRUG ANTIBODY RATIO; DRUG CONJUGATION; DRUG DESIGN; DRUG TARGETING; HUMAN; MICROTUBULE ASSEMBLY; NONHUMAN; PHARMACOLOGICAL PARAMETERS; REVIEW;

EID: 85046164803     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph11020032     Document Type: Review

References (125)

1. WHO: Cancer World Health Organization. Available online: http://www.who.int/mediacentre/factsheets/ fs297/en/ (accessed on 5 April 2018).
2. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751–760. [CrossRef] [PubMed]
3. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of atp-dependent transporters. Nat. Rev. Cancer 2002, 2, 48–58. [CrossRef] [PubMed]
4. Strebhardt, K.; Ullrich, A. Paul ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev. Cancer 2008, 8, 473–480. [CrossRef] [PubMed]
5. Panowski, S.; Bhakta, S.; Raab, H.; Polakis, P.; Junutula, J.R. Site-specific antibody drug conjugates for cancer therapy. mAbs 2014, 6, 34–45. [CrossRef] [PubMed]
6. Chari, R.V.J.; Miller, M.L.; Widdison, W.C. Antibody–drug conjugates: An emerging concept in cancer therapy. Angew. Chem. Int. Ed. 2014, 53, 3796–3827. [CrossRef] [PubMed]
7. Carter, P.J.; Senter, P.D. Antibody-drug conjugates for cancer therapy. Cancer J. 2008, 14, 154–169. [CrossRef] [PubMed]
8. Milstein, G.K.C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256, 495–497.
9. Rudnick, S.I.; Lou, J.; Shaller, C.C.; Tang, Y.; Klein-Szanto, A.J.P.; Weiner, L.M.; Marks, J.D.; Adams, G.P. Influence of affinity and antigen internalization on the uptake and penetration of anti-her2 antibodies in solid tumors. Cancer Res. 2011, 71, 2250–2259. [CrossRef] [PubMed]
10. Lin, K.; Tibbitts, J. Pharmacokinetic considerations for antibody drug conjugates. Pharm. Res. 2012, 29, 2354–2366. [CrossRef] [PubMed]
11. Tolcher, A.W.; Ochoa, L.; Hammond, L.A.; Patnaik, A.; Edwards, T.; Takimoto, C.; Smith, L.; de Bono, J.; Schwartz, G.; Mays, T. et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the canag antigen: A phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. 2003, 21, 211–222. [CrossRef] [PubMed]
12. Pastuskovas, C.V.; Mallet, W.; Clark, S.; Kenrick, M.; Majidy, M.; Schweiger, M.; Van Hoy, M.; Tsai, S.P.; Bennett, G.; Shen, B.-Q. Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA 125. Drug Metab. Dispos. 2010, 38, 2309–2319. [CrossRef] [PubMed]
13. Jiang, X.-R.; Song, A.; Bergelson, S.; Arroll, T.; Parekh, B.; May, K.; Chung, S.; Strouse, R.; Mire-Sluis, A.; Schenerman, M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug Discov. 2011, 10, 101–111. [CrossRef] [PubMed]
14. Sapra, P.; Hooper, A.T.; O’Donnell, C.J.; Gerber, H.P. Investigational antibody drug conjugates for solid tumors. Expert Opin. Investig. Drugs 2011, 20, 1131–1149. [CrossRef] [PubMed]
15. Junttila, T.T.; Li, G.; Parsons, K.; Phillips, G.L.; Sliwkowski, M.X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 2011, 128, 347–356. [CrossRef] [PubMed]
16. Sharkey, R.M.; Goldenberg, D.M. Targeted therapy of cancer: New prospects for antibodies and immunoconjugates. CA-A Cancer J. Clin. 2006, 56, 226–243. [CrossRef]
17. Pillay, C.S.; Elliott, E.; Dennison, C. Endolysosomal proteolysis and its regulation. Biochem. J. 2002, 363, 417–429. [CrossRef] [PubMed]
18. Alley, S.C.; Okeley, N.M.; Senter, P.D. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 2010, 14, 529–537. [CrossRef] [PubMed]
19. Griffith, O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med. 1999, 27, 922–935. [CrossRef]
20. Balendiran, G.K.; Dabur, R.; Fraser, D. The role of glutathione in cancer. Cell Biochem. Funct. 2004, 22, 343–352. [CrossRef] [PubMed]
21. Wu, G.; Fang, Y.-Z.; Yang, S.; Lupton, J.R.; Turner, N.D. Glutathione metabolism and its implications for health. J. Nutr. 2004, 134, 489–492. [CrossRef] [PubMed]
22. Appenzeller-Herzog, C.; Ellgaard, L. The human pdi family: Versatility packed into a single fold. BBA-Mol. Cell. Res. 2008, 1783, 535–548. [CrossRef] [PubMed]
23. Chari, R.V.J. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc. Chem. Res. 2008, 41, 98–107. [CrossRef] [PubMed]
24. Dubowchik, G.M.; Firestone, R.A. Cathepsin b-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett. 1998, 8, 3341–3346. [CrossRef]
25. Tranoy-Opalinski, I.; Legigan, T.; Barat, R.; Clarhaut, J.; Thomas, M.; Renoux, B.; Papot, S. Beta-glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update. Eur. J. Med. Chem. 2014, 74, 302–313. [CrossRef] [PubMed]
26. Michelle de, G.; Epie, B.; Hans, W.S.; Hidde, J.H.; Herbert, M.P. Beta-glucuronidase-mediated drug release. Curr. Pharm. Des. 2002, 8, 1391–1403.
27. Jeffrey, S.C.; Andreyka, J.B.; Bernhardt, S.X.; Kissler, K.M.; Kline, T.; Lenox, J.S.; Moser, R.F.; Nguyen, M.T.; Okeley, N.M.; Stone, I.J. et al. Development and properties of β-glucuronide linkers for monoclonal antibody—drug conjugates. Bioconj. Chem. 2006, 17, 831–840. [CrossRef] [PubMed]
28. Jeffrey, S.C.; De Brabander, J.; Miyamoto, J.; Senter, P.D. Expanded utility of the β-glucuronide linker: ADCs that deliver phenolic cytotoxic agents. ACS Med. Chem. Lett. 2010, 1, 277–280. [CrossRef] [PubMed]
29. Burke, P.J.; Hamilton, J.Z.; Pires, T.A.; Setter, J.R.; Hunter, J.H.; Cochran, J.H.; Waight, A.B.; Gordon, K.A.; Toki, B.E.; Emmerton, K.K. et al. Development of novel quaternary ammonium linkers for antibody–drug conjugates. Mol. Cancer Ther. 2016, 15, 938–945. [CrossRef] [PubMed]
30. Senter, P.D.; Sievers, E.L. The discovery and development of brentuximab vedotin for use in relapsed hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 2012, 30, 631–637. [CrossRef] [PubMed]
31. Diamantis, N.; Banerji, U. Antibody-drug conjugates—An emerging class of cancer treatment. Br. J. Cancer 2016, 114, 362–367. [CrossRef] [PubMed]
32. LoRusso, P.M.; Weiss, D.; Guardino, E.; Girish, S.; Sliwkowski, M.X. Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2–positive cancer. Clin. Cancer Res. 2011, 17, 6437–6447. [CrossRef] [PubMed]
33. Kovtun, Y.V.; Audette, C.A.; Mayo, M.F.; Jones, G.E.; Doherty, H.; Maloney, E.K.; Erickson, H.K.; Sun, X.; Wilhelm, S.; Ab, O. et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010, 70, 2528–2537. [CrossRef] [PubMed]
34. Doronina, S.O.; Mendelsohn, B.A.; Bovee, T.D.; Cerveny, C.G.; Alley, S.C.; Meyer, D.L.; Oflazoglu, E.; Toki, B.E.; Sanderson, R.J.; Zabinski, R.F.; et al. Enhanced activity of monomethylauristatin f through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconj. Chem. 2006, 17, 114–124. [CrossRef] [PubMed]
35. Loganzo, F.; Sung, M.; Gerber, H.-P. Mechanisms of resistance to antibody–drug conjugates. Mol. Cancer Ther. 2016, 15, 2825–2834. [CrossRef] [PubMed]
36. Parslow, A.; Parakh, S.; Lee, F.-T.; Gan, H.; Scott, A. Antibody–drug conjugates for cancer therapy. Biomedicines 2016, 4, 14. [CrossRef] [PubMed]
37. Linenberger, M.L.; Hong, T.; Flowers, D.; Sievers, E.L.; Gooley, T.A.; Bennett, J.M.; Berger, M.S.; Leopold, L.H.; Appelbaum, F.R.; Bernstein, I.D. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001, 98, 988–994. [CrossRef] [PubMed]
38. Shefet-Carasso, L.; Benhar, I. Antibody-targeted drugs and drug resistance–challenges and solutions. Drug Resist. Updates 2015, 18, 36–46. [CrossRef] [PubMed]
39. Zhao, R.Y.; Wilhelm, S.D.; Audette, C.; Jones, G.; Leece, B.A.; Lazar, A.C.; Goldmacher, V.S.; Singh, R.; Kovtun, Y.; Widdison, W.C. et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J. Med. Chem. 2011, 54, 3606–3623. [CrossRef] [PubMed]
40. Ducry, L.; Stump, B. Antibody—drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconj. Chem. 2010, 21, 5–13. [CrossRef] [PubMed]
41. Trail, P.; Willner, D.; Lasch, S.; Henderson, A.; Hofstead, S.; Casazza, A.; Firestone, R.; Hellstrom, I.; Hellstrom, K. Cure of xenografted human carcinomas by Br96-doxorubicin immunoconjugates. Science 1993, 261, 212–215. [CrossRef] [PubMed]
42. Tolcher, A.W.; Sugarman, S.; Gelmon, K.A.; Cohen, R.; Saleh, M.; Isaacs, C.; Young, L.; Healey, D.; Onetto, N.; Slichenmyer, W. Randomized phase ii study of br96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 1999, 17, 478–484. [CrossRef] [PubMed]
43. Maiese, W.M.; Lechevalier, M.P.; Lechevalier, H.A.; Korshalla, J.; Kuck, N.; Fantini, A.; Wildey, M.J.; Thomas, J.; Greenstein, M. Calicheamicins, a novel family of antitumor antibiotics: Taxonomy, fermentation and biological properties. J. Antibiot. 1989, 42, 558–563. [CrossRef] [PubMed]
44. Polakis, P. Antibody drug conjugates for cancer therapy. Pharmacol. Rev. 2016, 68, 3–19. [CrossRef] [PubMed]
45. Jones, R.R.; Bergman, R.G. P-benzyne. Generation as an intermediate in a thermal isomerization reaction and trapping evidence for the 1,4-benzenediyl structure. J. Am. Chem. Soc. 1972, 94, 660–661. [CrossRef]
46. Watanabe, C.M.; Supekova, L.; Schultz, P.G. Transcriptional effects of the potent enediyne anti-cancer agent calicheamicin gamma(i)(1). Chem. Biol. 2002, 9, 245–251. [CrossRef]
47. De Vries, J.F.; Zwaan, C.M.; De Bie, M.; Voerman, J.S.; den Boer, M.L.; van Dongen, J.J.; van der Velden, V.H. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 2012, 26, 255–264. [CrossRef] [PubMed]
48. Elgersma, R.C.; Coumans, R.G.; Huijbregts, T.; Menge, W.M.; Joosten, J.A.; Spijker, H.J.; de Groot, F.M.; van der Lee, M.M.; Ubink, R.; van den Dobbelsteen, D.J. et al. Design, synthesis, and evaluation of linker-duocarmycin payloads: Toward selection of HER2-targeting antibody-drug conjugate SYD 985. Mol. Pharm. 2015, 12, 1813–1835. [CrossRef] [PubMed]
49. Li, W.; Khullar, A.; Chou, S.; Sacramo, A.; Gerratana, B. Biosynthesis of sibiromycin, a potent antitumor antibiotic. Appl. Environ. Microbiol. 2009, 75, 2869–2878. [CrossRef] [PubMed]
50. Bouchard, H.; Viskov, C.; Garcia-Echeverria, C. Antibody-drug conjugates—A new wave of cancer drugs. Bioorg. Med. Chem. Lett. 2014, 24, 5357–5363. [CrossRef] [PubMed]
51. Mantaj, J.; Jackson, P.J.; Rahman, K.M.; Thurston, D.E. From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs). Angew. Chem. Int. Ed. Engl. 2017, 56, 462–488. [CrossRef] [PubMed]
52. Amador, M.L.; Jimeno, J.; Paz-Ares, L.; Cortes-Funes, H.; Hidalgo, M. Progress in the development and acquisition of anticancer agents from marine sources. Ann. Oncol. 2003, 14, 1607–1615. [CrossRef] [PubMed]
53. Pettit, G.R.; Srirangam, J.K.; Barkoczy, J.; Williams, M.D.; Boyd, M.R.; Hamel, E.; Pettit, R.K.; Hogan, F.; Bai, R.; Chapuis, J.C. et al. Antineoplastic agents 365. Dolastatin 10 sar probes. Anticancer Drug Des. 1998, 13, 243–277. [PubMed]
54. Pettit, R.K.; Pettit, G.R.; Hazen, K.C. Specific activities of dolastatin 10 and peptide derivatives against cryptococcus neoformans. Antimicrob. Agents Chemother. 1998, 42, 2961–2965. [PubMed]
55. Bai, R.L.; Pettit, G.R.; Hamel, E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J. Biol. Chem. 1990, 265, 17141–17149. [PubMed]
56. Katz, J.; Janik, J.E.; Younes, A. Brentuximab vedotin (SGN-35). Clin. Cancer Res. 2011, 17, 6428–6436. [CrossRef] [PubMed]
57. Liu, J.F.; Moore, K.N.; Birrer, M.J.; Berlin, S.; Matulonis, U.A.; Infante, J.R.; Wolpin, B.; Poon, K.A.; Firestein, R.; Xu, J. et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann. Oncol. 2016, 27, 2124–2130. [CrossRef] [PubMed]
58. Tai, Y.T.; Mayes, P.A.; Acharya, C.; Zhong, M.Y.; Cea, M.; Cagnetta, A.; Craigen, J.; Yates, J.; Gliddon, L.; Fieles, W. et al. Novel anti-b-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 2014, 123, 3128–3138. [CrossRef] [PubMed]
59. Francisco, J.A.; Cerveny, C.G.; Meyer, D.L.; Mixan, B.J.; Klussman, K.; Chace, D.F.; Rejniak, S.X.; Gordon, K.A.; DeBlanc, R.; Toki, B.E. et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102, 1458–1465. [CrossRef] [PubMed]
60. Li, F.; Emmerton, K.K.; Jonas, M.; Zhang, X.; Miyamoto, J.B.; Setter, J.R.; Nicholas, N.D.; Okeley, N.M.; Lyon, R.P.; Benjamin, D.R. et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 2016, 76, 2710–2719. [CrossRef] [PubMed]
61. Kupchan, S.M.; Komoda, Y.; Court, W.A.; Thomas, G.J.; Smith, R.M.; Karim, A.; Gilmore, C.J.; Haltiwanger, R.C.; Bryan, R.F. Maytansine, a novel antileukemic ansa macrolide from maytenus ovatus. J. Am. Chem. Soc. 1972, 94, 1354–1356. [CrossRef] [PubMed]
62. Kupchan, S.M.; Komoda, Y.; Branfman, A.R.; Sneden, A.T.; Court, W.A.; Thomas, G.J.; Hintz, H.P.; Smith, R.M.; Karim, A.; Howie, G.A. et al. The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. J. Org. Chem. 1977, 42, 2349–2357. [CrossRef] [PubMed]
63. Mandelbaum-Shavit, F.; Wolpert-DeFilippes, M.K.; Johns, D.G. Binding of maytansine to rat brain tubulin. Biochem. Biophys. Res. Commun. 1976, 72, 47–54. [CrossRef]
64. Widdison, W.C.; Wilhelm, S.D.; Cavanagh, E.E.; Whiteman, K.R.; Leece, B.A.; Kovtun, Y.; Goldmacher, V.S.; Xie, H.; Steeves, R.M.; Lutz, R.J. et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 2006, 49, 4392–4408. [CrossRef] [PubMed]
65. Blanc, V.; Bousseau, A.; Caron, A.; Carrez, C.; Lutz, R.J.; Lambert, J.M. Sar3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin. Cancer Res. 2011, 17, 6448–6458. [CrossRef] [PubMed]
66. Lindell, T.J.; Weinberg, F.; Morris, P.W.; Roeder, R.G.; Rutter, W.J. Specific inhibition of nuclear RNA polymerase II by alpha-amanitin. Science 1970, 170, 447–449. [CrossRef] [PubMed]
67. Anderl, J.; Müller, C.; Heckl-Östreicher, B.; Wehr, R. Abstract 3616: Highly potent antibody-amanitin conjugates cause tumor-selective apoptosis. Cancer Res. 2011, 71, 3616. [CrossRef]
68. Moldenhauer, G.; Salnikov, A.V.; Luttgau, S.; Herr, I.; Anderl, J.; Faulstich, H. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J. Natl. Cancer Inst. 2012, 104, 622–634. [CrossRef] [PubMed]
69. Hechler, T.; Kulke, M.; Mueller, C.; Pahl, A.; Anderl, J. Abstract 664: Amanitin-based antibody-drug conjugates targeting the prostate-specific membrane antigen. Cancer Res. 2014, 74. [CrossRef]
70. Hamblett, K.J.; Senter, P.D.; Chace, D.F.; Sun, M.M.; Lenox, J.; Cerveny, C.G.; Kissler, K.M.; Bernhardt, S.X.; Kopcha, A.K.; Zabinski, R.F. et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 2004, 10, 7063–7070. [CrossRef] [PubMed]
71. Doronina, S.O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Cerveny, C.G.; Chace, D.F.; DeBlanc, R.L.; Gearing, R.P.; Bovee, T.D.; Siegall, C.B. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 21, 778–784. [CrossRef] [PubMed]
72. McAuley, A.; Jacob, J.; Kolvenbach, C.G.; Westland, K.; Lee, H.J.; Brych, S.R.; Rehder, D.; Kleemann, G.R.; Brems, D.N.; Matsumura, M. Contributions of a disulfide bond to the structure, stability, and dimerization of human igg1 antibody ch3 domain. Protein Sci. 2008, 17, 95–106. [CrossRef] [PubMed]
73. Sun, M.M.; Beam, K.S.; Cerveny, C.G.; Hamblett, K.J.; Blackmore, R.S.; Torgov, M.Y.; Handley, F.G.; Ihle, N.C.; Senter, P.D.; Alley, S.C. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconj. Chem. 2005, 16, 1282–1290. [CrossRef] [PubMed]
74. Schroeder, D.D.; Tankersley, D.L.; Lundblad, J.L. A new preparation of modified immune serum globulin (human) suitable for intravenous administration. I. Standardization of the reduction and alkylation reaction. Vox Sang. 1981, 40, 373–382. [CrossRef] [PubMed]
75. Agarwal, P.; Bertozzi, C.R. Site-specific antibody–drug conjugates: The nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconj. Chem. 2015, 26, 176–192. [CrossRef] [PubMed]
76. Hamann, P.R.; Hinman, L.M.; Hollander, I.; Beyer, C.F.; Lindh, D.; Holcomb, R.; Hallett, W.; Tsou, H.R.; Upeslacis, J.; Shochat, D.; et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 2002, 13, 47–58. [CrossRef] [PubMed]
77. Burnett, A.K.; Hills, R.K.; Milligan, D.; Kjeldsen, L.; Kell, J.; Russell, N.H.; Yin, J.A.; Hunter, A.; Goldstone, A.H.; Wheatley, K. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the mrc aml15 trial. J. Clin. Oncol. 2011, 29, 369–377. [CrossRef] [PubMed]
78. Luo, Q.; Chung, H.H.; Borths, C.; Janson, M.; Wen, J.; Joubert, M.K.; Wypych, J. Structural characterization of a monoclonal antibody-maytansinoid immunoconjugate. Anal. Chem. 2016, 88, 695–702. [CrossRef] [PubMed]
79. Adem, Y.T.; Schwarz, K.A.; Duenas, E.; Patapoff, T.W.; Galush, W.J.; Esue, O. Auristatin antibody drug conjugate physical instability and the role of drug payload. Bioconj. Chem. 2014, 25, 656–664. [CrossRef] [PubMed]
80. Moussa, E.M.; Panchal, J.P.; Moorthy, B.S.; Blum, J.S.; Joubert, M.K.; Narhi, L.O.; Topp, E.M. Immunogenicity of therapeutic protein aggregates. J. Pharm. Sci. 2016, 105, 417–430. [CrossRef] [PubMed]
81. McDonagh, C.F.; Turcott, E.; Westendorf, L.; Webster, J.B.; Alley, S.C.; Kim, K.; Andreyka, J.; Stone, I.; Hamblett, K.J.; Francisco, J.A. et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng. Des. Sel. 2006, 19, 299–307. [CrossRef] [PubMed]
82. Yurkovetskiy, A.V.; Yin, M.; Bodyak, N.; Stevenson, C.A.; Thomas, J.D.; Hammond, C.E.; Qin, L.; Zhu, B.; Gumerov, D.R.; Ter-Ovanesyan, E. et al. A polymer-based antibody–vinca drug conjugate platform: Characterization and preclinical efficacy. Cancer Res. 2015, 75, 3365–3372. [CrossRef] [PubMed]
83. Krop, I.; Winer, E.P. Trastuzumab emtansine: A novel antibody-drug conjugate for HER2-positive breast cancer. Clin. Cancer Res. 2014, 20, 15–20. [CrossRef] [PubMed]
84. Tsuchikama, K.; An, Z. Antibody-drug conjugates: Recent advances in conjugation and linker chemistries. Protein Cell 2018, 9, 33–46. [CrossRef] [PubMed]
85. Chen, Y. Drug-to-antibody ratio (DAR) by UV/vis spectroscopy. Methods Mol. Med. 2013, 1045, 267–273.
86. Wang, L.; Amphlett, G.; Blättler, W.A.; Lambert, J.M.; Zhang, W. Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, HUN901–DM1, by mass spectrometry. Protein Sci. 2005, 14, 2436–2446. [CrossRef] [PubMed]
87. Hudecz, F.; Garnett, M.C.; Khan, T.; Baldwin, R.W. The influence of synthetic conditions on the stability of methotrexate-monoclonal antibody conjugates determined by reversed phase high performance liquid chromatography. Biomed. Chromatogr. 1992, 6, 128–132. [CrossRef] [PubMed]
88. Ouyang, J. Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography. Methods Mol. Biol. 2013, 1045, 275–283. [PubMed]
89. Chen, T.; Zhang, K.; Gruenhagen, J.; Medley, C.D.; Hydrophobic interaction chromatography for antibody drug conjugate drug distribution analysis. Am. Pharm. Rev. 2015. Available online: https://www.americanpharmaceuticalreview.com/Featured-Articles/177927-Hydrophobic-Interaction-Chromatography-for-Antibody-Drug-Conjugate-Drug-Distribution-Analysis/ (accessed on 3 April 2018).
90. Basa, L. Drug-to-antibody ratio (DAR) and drug load distribution by lc-esi-ms. Methods Mol. Biol. 2013, 1045, 285–293. [PubMed]
91. Huang, R.Y.C.; Chen, G. Characterization of antibody–drug conjugates by mass spectrometry: Advances and future trends. Drug Discov. Today 2016, 21, 850–855. [CrossRef] [PubMed]
92. Wagner-Rousset, E.; Janin-Bussat, M.C.; Colas, O.; Excoffier, M.; Ayoub, D.; Haeuw, J.F.; Rilatt, I.; Perez, M.; Corvaia, N.; Beck, A. Antibody-drug conjugate model fast characterization by lc-ms following ides proteolytic digestion. mAbs 2014, 6, 273–285. [CrossRef] [PubMed]
93. Junutula, J.R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D.D.; Weir, S.; Chen, Y.; Simpson, M.; Tsai, S.P.; Dennis, M.S. et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 2008, 26, 925–932. [CrossRef] [PubMed]
94. Axup, J.Y.; Bajjuri, K.M.; Ritland, M.; Hutchins, B.M.; Kim, C.H.; Kazane, S.A.; Halder, R.; Forsyth, J.S.; Santidrian, A.F.; Stafin, K. et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. USA 2012, 109, 16101–16106. [CrossRef] [PubMed]
95. Jeger, S.; Zimmermann, K.; Blanc, A.; Grunberg, J.; Honer, M.; Hunziker, P.; Struthers, H.; Schibli, R. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew. Chem. Int. Ed. Engl. 2010, 49, 9995–9997. [CrossRef] [PubMed]
96. Junutula, J.R.; Bhakta, S.; Raab, H.; Ervin, K.E.; Eigenbrot, C.; Vandlen, R.; Scheller, R.H.; Lowman, H.B. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-fabs. J. Immunol. Methods 2008, 332, 41–52. [CrossRef] [PubMed]
97. Junutula, J.R.; Flagella, K.M.; Graham, R.A.; Parsons, K.L.; Ha, E.; Raab, H.; Bhakta, S.; Nguyen, T.; Dugger, D.L.; Li, G. et al. Engineered thio-trastuzumab-dm1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin. Cancer Res. 2010, 16, 4769–4778. [CrossRef] [PubMed]
98. Yao, H.; Jiang, F.; Lu, A.; Zhang, G. Methods to design and synthesize antibody-drug conjugates (adcs). Int. J. Mol. Sci. 2016, 17, 194. [CrossRef] [PubMed]
99. Hallam, T.J.; Smider, V.V. Unnatural amino acids in novel antibody conjugates. Future Med. Chem. 2014, 6, 1309–1324. [CrossRef] [PubMed]
100. Liu, C.C.; Schultz, P.G. Adding new chemistries to the genetic code. Annu. Rev. Biochem. 2010, 79, 413–444. [CrossRef] [PubMed]
101. Tian, F.; Lu, Y.; Manibusan, A.; Sellers, A.; Tran, H.; Sun, Y.; Phuong, T.; Barnett, R.; Hehli, B.; Song, F. et al. A general approach to site-specific antibody drug conjugates. Proc. Natl. Acad. Sci. USA 2014, 111, 1766–1771. [CrossRef] [PubMed]
102. Yokoyama, K.; Nio, N.; Kikuchi, Y. Properties and applications of microbial transglutaminase. Appl. Microbiol. Biotechnol. 2004, 64, 447–454. [CrossRef] [PubMed]
103. Strop, P.; Liu, S.H.; Dorywalska, M.; Delaria, K.; Dushin, R.G.; Tran, T.T.; Ho, W.H.; Farias, S.; Casas, M.G.; Abdiche, Y. et al. Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 2013, 20, 161–167. [CrossRef] [PubMed]
104. Strop, P.; Tran, T.T.; Dorywalska, M.; Delaria, K.; Dushin, R.; Wong, O.K.; Ho, W.H.; Zhou, D.; Wu, A.; Kraynov, E. et al. RN927C, a site-specific trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models. Mol. Cancer Ther. 2016, 15, 2698–2708. [CrossRef] [PubMed]
105. Carrico, I.S.; Carlson, B.L.; Bertozzi, C.R. Introducing genetically encoded aldehydes into proteins. Nat. Chem. Biol. 2007, 3, 321–322. [CrossRef] [PubMed]
106. Agarwal, P.; van der Weijden, J.; Sletten, E.M.; Rabuka, D.; Bertozzi, C.R. A pictet-spengler ligation for protein chemical modification. Proc. Natl. Acad. Sci. USA 2013, 110, 46–51. [CrossRef] [PubMed]
107. Agarwal, P.; Kudirka, R.; Albers, A.E.; Barfield, R.M.; de Hart, G.W.; Drake, P.M.; Jones, L.C.; Rabuka, D. Hydrazino-pictet-spengler ligation as a biocompatible method for the generation of stable protein conjugates. Bioconj. Chem. 2013, 24, 846–851. [CrossRef] [PubMed]
108. Starodub, A.N.; Ocean, A.J.; Shah, M.A.; Vahdat, L.T.; Chuang, E.; Guarino, M.J.; Picozzi, V.J.; Thomas, S.S.; Maliakal, P.P.; Govindan, S.V. et al. Abstract CT206: SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results. Cancer Res. 2014, 74, CT206. [CrossRef]
109. Goldenberg, D.M.; Cardillo, T.M.; Govindan, S.V.; Rossi, E.A.; Sharkey, R.M. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (immu-132), an antibody-drug conjugate (ADC). Oncotarget 2015, 6, 22496–22512. [CrossRef] [PubMed]
110. Bardia, A.; Vahdat, L.T.; Diamond, J.R.; Starodub, A.; Moroose, R.L.; Isakoff, S.J.; Ocean, A.J.; Berlin, J.; Messersmith, W.A.; Thomas, S.S. et al. Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. J. Clin. Oncol. 2015, 33, 1016. [CrossRef]
111. Elnakat, H.; Ratnam, M. Distribution, functionality and gene regulation of folate receptor isoforms: Implications in targeted therapy. Adv. Drug Deliv. Rev. 2004, 56, 1067–1084. [CrossRef] [PubMed]
112. Ab, O.; Whiteman, K.R.; Bartle, L.M.; Sun, X.; Singh, R.; Tavares, D.; LaBelle, A.; Payne, G.; Lutz, R.J.; Pinkas, J. et al. Imgn853, a folate receptor-α (FRα)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against fralpha-expressing tumors. Mol. Cancer Ther. 2015, 14, 1605–1613. [CrossRef] [PubMed]
113. Erickson, H.K.; Park, P.U.; Widdison, W.C.; Kovtun, Y.V.; Garrett, L.M.; Hoffman, K.; Lutz, R.J.; Goldmacher, V.S.; Blattler, W.A. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006, 66, 4426–4433. [CrossRef] [PubMed]
114. Ponte, J.F.; Ab, O.; Lanieri, L.; Lee, J.; Coccia, J.; Bartle, L.M.; Themeles, M.; Zhou, Y.; Pinkas, J.; Ruiz-Soto, R. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models. Neoplasia 2016, 18, 775–784. [CrossRef] [PubMed]
115. Moore, K.N.; Borghaei, H.; O’Malley, D.M.; Jeong, W.; Seward, S.M.; Bauer, T.M.; Perez, R.P.; Matulonis, U.A.; Running, K.L.; Zhang, X. et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors. Cancer 2017, 123, 3080–3087. [CrossRef] [PubMed]
116. Moore, K.N.; Martin, L.P.; O’Malley, D.M.; Matulonis, U.A.; Konner, J.A.; Perez, R.P.; Bauer, T.M.; Ruiz-Soto, R.; Birrer, M.J. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A phase i expansion study. J. Clin. Oncol. 2017, 35, 1112–1118. [CrossRef] [PubMed]
117. Tedder, T.F.; Tuscano, J.; Sato, S.; Kehrl, J.H. Cd22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu. Rev. Immunol. 1997, 15, 481–504. [CrossRef] [PubMed]
118. Piccaluga, P.P.; Arpinati, M.; Candoni, A.; Laterza, C.; Paolini, S.; Gazzola, A.; Sabattini, E.; Visani, G.; Pileri, S.A. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk. lymphoma 2011, 52, 325–327. [CrossRef] [PubMed]
119. DiJoseph, J.F.; Dougher, M.M.; Evans, D.Y.; Zhou, B.-B.; Damle, N.K. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with cvp or chop. Cancer Chemother. Pharmacol. 2011, 67, 741–749. [CrossRef] [PubMed]
120. Advani, A.; Coiffier, B.; Czuczman, M.S.; Dreyling, M.; Foran, J.; Gine, E.; Gisselbrecht, C.; Ketterer, N.; Nasta, S.; Rohatiner, A. et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-hodgkin’s lymphoma: Results of a phase i study. J. Clin. Oncol. 2010, 28, 2085–2093. [CrossRef] [PubMed]
121. Goy, A.; Forero, A.; Wagner-Johnston, N.; Christopher Ehmann, W.; Tsai, M.; Hatake, K.; Ananthakrishnan, R.; Volkert, A.; Vandendries, E.; Ogura, M. A phase 2 study of inotuzumab ozogamicin in patients with indolent b-cell non-hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br. J. Haematol. 2016, 174, 571–581. [CrossRef] [PubMed]
122. Teicher, B.A.; Chari, R.V. Antibody conjugate therapeutics: Challenges and potential. Clin. Cancer Res. 2011, 17, 6389–6397. [CrossRef] [PubMed]
123. Singh, S.K.; Luisi, D.L.; Pak, R.H. Antibody-drug conjugates: Design, formulation and physicochemical stability. Pharm. Res. 2015, 32, 3541–3571. [CrossRef] [PubMed]
124. Kennedy, P.J.; Oliveira, C.; Granja, P.L.; Sarmento, B. Antibodies and associates: Partners in targeted drug delivery. Pharmacol. Ther. 2017, 177, 129–145. [CrossRef] [PubMed]
125. Zolot, R.S.; Basu, S.; Million, R.P. Antibody-drug conjugates. Nat. Rev. Drug Discov. 2013, 12, 259–260. [CrossRef] [PubMed]